These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3623)

  • 1. Predicting individual responses to drug treatment in schizophrenia: a test dose model.
    May PR; Van Putten T; Yale C; Potepan P; Jenden DJ; Fairchild MD; Goldstein MJ; Dixon WJ
    J Nerv Ment Dis; 1976 Mar; 162(3):177-83. PubMed ID: 3623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method.
    Yamanouchi Y; Sukegawa T; Inagaki A; Inada T; Yoshio T; Yoshimura R; Iwata N
    Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25522380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose selection and comparator drugs in schizophrenia research.
    Kane JM
    J Clin Psychiatry; 2001; 62 Suppl 9():29-32; discussion 33-4. PubMed ID: 11379828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natural course of schizophrenia and effective maintenance drug treatment.
    Davis JM; Andriukaitis S
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):2S-10S. PubMed ID: 2870087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive findings for negative symptoms of schizophrenia: no longer untreatable?
    Stahl SM
    Acta Psychiatr Scand; 2006 Nov; 114(5):301-2. PubMed ID: 17022789
    [No Abstract]   [Full Text] [Related]  

  • 6. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics and cognition in schizophrenia.
    Sharma T
    Arch Gen Psychiatry; 2002 Jun; 59(6):571-2; author reply 573-5. PubMed ID: 12044209
    [No Abstract]   [Full Text] [Related]  

  • 8. Higher than recommended dosages of antipsychotics in male patients with schizophrenia are associated with increased depression but no major neurocognitive side effects: Results of a cross-sectional pilot naturalistic study.
    Fountoulakis KN; Gonda X; Siamouli M; Moutou K; Nitsa Z; Leonard BE; Kasper S
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():113-119. PubMed ID: 28137432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
    Kawai N; Yamakawa Y; Baba A; Nemoto K; Tachikawa H; Hori T; Asada T; Iidaka T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1009-14. PubMed ID: 16644082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
    Weiss E; Kemmler G; Fleischhacker WW
    Arch Gen Psychiatry; 2002 Jun; 59(6):572-3; author reply 573-5. PubMed ID: 12044210
    [No Abstract]   [Full Text] [Related]  

  • 11. Dose-response relationship of sertindole and haloperidol using the pharmacopsychometric triangle.
    Bech P; Tanghøj P; Andreasson K; Overø KF
    Acta Psychiatr Scand; 2011 Feb; 123(2):154-61. PubMed ID: 20560900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries.
    Barbui C; Nosè M; Mazzi MA; Thornicroft G; Schene A; Becker T; Bindman J; Leese M; Helm H; Koeter M; Weinmann S; Tansella M
    Int Clin Psychopharmacol; 2006 Nov; 21(6):355-62. PubMed ID: 17012982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Second generation of neuroleptics--expectations and the reality].
    Jarema M
    Psychiatr Pol; 2002; 36(6 Suppl):209-16. PubMed ID: 12647441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formation of immature neutrophil leucocytes in schizophrenic patients treated with various antipsychotic drugs: comparisons and predictions.
    Delieu JM; Horobin RW; Duguid JK
    J Psychopharmacol; 2006 Nov; 20(6):824-8. PubMed ID: 16401649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choice of and decreasing of the dosage of risperidone in the treatment of schizophrenia. Global versus individual criteria.
    Gómez-Perretta C
    Actas Esp Psiquiatr; 2007; 35(1):77-8. PubMed ID: 17323229
    [No Abstract]   [Full Text] [Related]  

  • 16. Important issues in the drug treatment of schizophrenia.
    Davis JM; Schaffer CB; Killian GA; Kinard C; Chan C
    Schizophr Bull; 1980; 6(1):70-87. PubMed ID: 6102795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic medication in the treatment of schizophrenia.
    Kane JM
    Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of drugs in schizophrenia. Basic trial design.
    Lader M
    Br J Clin Pharmacol; 1976 Jun; 3(3 Suppl 2):375-9. PubMed ID: 9964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.
    Shriqui CL
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S38-48. PubMed ID: 8564916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for enhancing drug therapy of schizophrenia.
    Schooler NR; Levine J
    Am J Psychother; 1983 Oct; 37(4):521-32. PubMed ID: 6140869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.